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We characterised biological properties of novel formulations of two low-potency glucocorticosteroids, dexamethasone and
hydrocortisone, which have an equivalent dose ratio of 1:50 in vasoconstriction tests. The rate of such carrier-mediated, mainly non-
diffusive glucocorticosteroids transport with very deformable lipid vesicles (TransfersomesR) through the skin, and the corresponding
cutaneous drug biodistribution data, were complemented with the drug bio-efficacy studies. The minimum effective drug dose that reduces
arachidonic acid-induced murine ear oedema by 50% was used as one bioactivity indicator. The minimum drug amount ensuring such an
effect in mouse skin decreases appreciably when a corticosteroid is applied epicutaneously with very deformable vesicles rather than a lotion
or a cre`me. Specifically, the minimum effective dose for hydrocortisone in very deformable carriers is 2–3 Ag cm 2 whereas for the cre`me-
or lotion-like preparations at least 10 Ag cm 2 is required. Such three- to fivefold relative increase of hydrocortisone potency is accompanied
by at least 13%, and more often >20%, absolute drug potency enhancement. The delivery of hydrocortisone with very deformable carriers
moreover prolongs the suppression of the drug-induced oedema nearly 2-fold (to f 24 h per application). The effective dose of
dexamethasone delivered with very deformable vesicles into murine skin is reduced >10 times compared with the cre`me- or lotion-based
products. Specifically, less than 0.1 Ag cm 2 dexamethasone in very deformable vesicles suppresses the arachidonic acid-induced murine ear
oedema >50%, on the average. Dexamethasone use on the skin in such vesicles extends the duration of drug action fourfold, compared with a
commercial cre`me, i.e. to >48 h per application. Epicutaneous use of glucocorticosteroids in very deformable vesicles also diminishes such
drug’s abrasion sensitivity and may increase the general robustness of drug effect. Lower frequency of skin treatment, which ensures
adequate biological response, is a result of this. Topical corticosteroid delivery with very deformable vesicles, TransfersomesR, thus
improves the therapeutic risk–benefit ratio, arguably due to better targeting into and longer drug presence in the skin.
D 2004 Elsevier B.V. All rights reserved.Keywords: Hydrocortisone; Dexamethasone; Drug carrier
1. Introduction The pharmacologic differences among various glucocor-Glucocorticoids were introduced in 1949 to treat rheu-
matoid arthritis. Since then, such drugs therapeutic applica-
tions grew in scope and now encompass numerous non-
endocrine and endocrine diseases [1]. Decades of intense
research effort also maximised the beneficial and minimised
the adverse side effects of glucocorticoids.0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2004.01.006
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1 Address during the study.ticosteroid derivatives result from structural alterations of
the basic steroid nucleus and its side groups. Drug bioavail-
ability, plasma half-life, and metabolic fate, but also the
modified glucocorticosteroid ability to bind to the glucocor-
ticoid receptor [2], and to modulate the transcription of
glucocorticoid-responsive genes [3], consequently have
been changed chemically. Furthermore, structural modifica-
tions diminished the natural cross-reactivity of glucocorti-
coids with the mineralocorticoid receptor and/or modified
the drug solubility in water [1].
Glucocorticoid activity has been defined mostly in rat
bioassays and does not always mimic the human response
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the growth-suppression by synthetic glucocorticoids.
Results of animal and in vitro receptor-binding, or cell-
stimulation studies, do not correlate with the tabulated
topical potency of common glucocorticoids either. Gluco-
corticoid potency is therefore defined in terms of drug’s
maximum dermal vasoconstriction effect [1]. It encom-
passes ultra-high potency (Class I) drugs, including clobe-
tasol- and halobetasol-propionate, and ends with low
potency (Class VII) drugs, such as dexamethasone, pred-
nisolone, and especially hydrocortisone.
Based on the duration of corticotropine suppression after
single dose application [2], which correlates reasonably well
with the biologic effect half-life, distinction is commonly
made between the short-, intermediate-, or long-acting
glucocorticosteroids. Hydrocortisone is a short-acting drug,
for example, with plasma and biologic half-life of approx-
imately 100 min and 8–12 h, respectively. Prednisolone has
an intermediate duration of action, with corresponding half-
lives of 115–200 min and 18–36 h. The long-acting
dexamethasone has half-lives of approximately 200 min
and 36–54 h, respectively.
Systemic absorption of epicutaneously administered glu-
cocorticoids depends on the state of the treated skin. Drug
absorption is highest in the damaged, inflamed, and occlud-
ed skin areas, or where the stratum corneum is thin (e.g. on
the eyelids, genitalia, and face).
Most corticosteroid dermatics contain skin permeation
enhancers [2] to promote drug absorption. Agent transfer
across the skin is further modified by changing the thermo-
dynamic activity of the drug on the skin, e.g. by choosing a
less potent (e.g. cre`me/lotion) or a more potent (e.g. oint-
ment) formulation, and occasionally by drug supersaturation
[4].
Lipid vesicles (liposomes) were proposed by some [5–
10] but not confirmed by other [11] researchers to increase
glucocorticosteroid concentration in the skin. Therapeutic
benefit of liposome-based corticosteroid dermatics in
humans was also found to be inconsistent [12]. This may
explain why no liposome-based corticosteroid formulation
has reached the market to date.
We developed self-regulating, lipid-based drug carriers,
so-called TransfersomesR2 (‘carrying bodies’) for targeted
and noninvasive delivery of agents into or through the
skin [13–18,25]. We also elucidated how such specially
designed vesicles overcome the skin permeability barrier
in the stratum corneum. The prerequisites are carrier
stability and self-deformation under stress [13–15] and
virtual pathways opening through the organ [16,17]. The
former two processes rely on local adjustment of the very
deformable vesicle composition to the surrounding stress
[13]. The latter originates from the transepidermal water
concentration gradient [15] and pushes the vesicles2 Transfersome is a trademark of IDEA AG.through the natural hydrophilic passages through the skin
[16], through which normally water evaporates. Very
deformable vesicles consequently transport drugs sponta-
neously into and across the non-occluded skin barrier
better than the previously tested vehicle systems [14,19–
21]. This increases biological activity of the preparations
based on very deformable vesicle over that of more
conventional topical corticosteroid formulations, and also
offers a means for controlling drug deposition into the
skin [18].
We previously published results of bioactivity measure-
ments with an intermediate potency glucocorticosteroid,
triamcinolone acetonide, delivered through the skin of mice
[19] and humans [20] with very deformable vesicles. To
complement the data, we now describe the corresponding
findings with two low potency corticosteroids, the short-
acting hydrocortisone and the very long-acting dexametha-
sone. For completeness we include some relevant drug
biodistribution data, which are described in greater detail
in Ref. [18].
Formulating either hydrocortisone or dexamethasone in
a suspension of very deformable vesicles significantly
lowers the therapeutically relevant concentration range to
around 0.1 wt.% and below 0.01 wt.%, respectively. This
is less than the respective concentrations of 0.25–2.5 wt.%
(mainly 1%) and 0.03–0.1 wt.% used in commercial
hydrocortisone and dexamethasone products. The biologi-
cal response time for the local corticosteroid action is
prolonged and the sensitivity of dexamethasone in very
deformable vesicles to abrasion is diminished. These find-
ings confirm our expectation that very deformable carriers
offer several advantages for topical delivery of glucocorti-
costeroids in the skin.2. Materials and methods
2.1. Formulation ingredients
Lipoid KG (Ludwigshafen, Germany) or Nattermann
Phospholipids-Rhone Poulenc Rorer (Cologne, Germany)
were our sources of soybean phosphatidylcholine (SPC)
with at least 95% purity. The membrane softening agent,
polysorbate, with nominally 20 oxyethylene units on each
molecule, was purchased from Henkel (Du¨sseldorf, Ger-
many) in pharmaceutical grade quality, and was included in
1:1 molar ratio relatively to SPC, unless specified otherwise.
Dexamethasone and hydrocortisone were obtained from
SynoPharm (Hamburg, Germany). Injectable quality, bi-
distilled water was acquired from a local pharmacy and
used to prepare all suspension buffers. Commercial drug
formulations were used for controls: Anemul creme (Phar-
masal, Gra¨feling, Germany), containing dexamethasone,
and Hydrocortisone-Wolff cre`me or lotion (Wolff, Bielefeld,
Germany). Tritiurated corticosteroids were obtained from
Amersham or ICN, and were used as received.
G. Cevc, G. Blume / Biochimica et Biophysica Acta 1663 (2004) 61–73 632.2. Test formulations
Test formulations used in animal experiments were
prepared with conventional film method. In short, a homo-
geneous solution of all water-insoluble components in
methanol/chloroform (1:1 v/v) was dried under a stream
of nitrogen. This yielded a thin, mixed, lipid plus agent
film in a round-bottom glass flask. The film was further
evacuated with a diffusion pump (10 Pa, 12 h) and
subsequently taken up in a buffer with pH = 6.5. This
yielded heterogeneous vesicles suspension, which was
homogenised by gentle sonication with a titanium micro-
tip (Heat Systems W 380, USA, < 30 min and 4 jC, under
nitrogen). The resulting suspension contained vesicles with
an average diameter between 100 and 200 nm, depending
on preparation, as determined with photon correlation
spectroscopy (ALV-5000, ALV-Laser Vertriebsgesellschaft,
Langen, Germany) using 90j scattering. The typical vesicle
size distribution width was around 30%. When required,
the bulk lipid suspension was diluted with the buffer used
to manufacture the original vesicle suspension to obtain
phosphatidylcholine concentration in the range 0.5 to 5
wt.%. (Changes in total lipid concentration were found to
have only a marginal, if any, effect on the outcome of
experiments, due to the non-diffusive nature of Trans-
fersomeR mediated transport [15].) Formulations thus
contained between 0.005 and 0.5 wt.% corticosteroid per
milliliter of suspension, depending on the final drug and
total lipid concentration. Liposomes comprised only SPC.
The very deformable mixed lipid vesicles (Trans-
fersomesR) contained an equimolar mixture of SPC and
polysorbate.
2.3. Animals
NMRI mice for in vivo experiments were purchased from
Charles-River (Germany). They were kept in a local facility,
for up to 8 weeks, under standard laboratory conditions (a
group of three to five mice of 8–12 weeks of age per
suspended cage; standard chow; water ad libitum; 12-h light/
dark regime), adhering to the ‘‘Principles of Laboratory
Animal Care’’ (NIH publication #85-23, revised in 1985).
Outbred pig was killed in a local slaughterhouse on the
day of experiment and afforded the skin for ex vivo experi-
ments shortly thereafter.
2.4. Artificial barrier penetration experiments
To establish which kind of vesicles is able to cross pores
smaller than the average aggregate size, two sets of experi-
ments were done. In the first set, very deformable (Trans-
fersomeR) and simple (liposome) vesicles, loaded with the
tested corticosteroid, were subjected to a low relative
pressure (0.2 MPa) and thus pushed into a polycarbonate
membrane perforated by 80-nm pores. In the other test
situation, the flux driving pressure was increased to 0.9MPa. The average vesicle size in either kind case was
around 200 nm.
2.5. Skin penetration experiments
Cutaneous samples were excised from the skin of mice
pretreated epicutaneously in vivo as is described in the
following section. Subcutaneous fatty tissue was carefully
removed with a scalpel. The outermost stratum corneum
layers were collected sequentially with five Scotch tape-
strippings and analysed individually. The remaining skin
tissue was dissolved, destained, and used for radioactivity
counting as has been described before [18].
To assess corticosteroid transport into porcine skin, ex
vivo, full thickness skin samples (20 to 30 cm2) were
excised from a fresh cadaver (less than 12 h old) and then
fixed on a wet substrate. Several test areas (1 cm2) on a
larger tissue were pre-marked with a water-resistant pen and
treated further as detailed for in vivo experiments with mice,
except in that the test formulation remained on the skin for 6
h at 32 jC.
2.6. Biodistribution studies
Biodistribution studies involved first the trimming of hair
on upper animal’s back with a pair of scissors on the day
before an experiment. The appropriate amount of drug
formulation (0.5 to 25 Al) was then applied epicutaneously
on the pre-marked area (typically f 1 cm2) with a positive
displacement micropipette. The applied volume was spread
as uniformly as possible over the selected skin surface,
using the side of application micropipette tip, and allowed to
dry. For each individual time point, 20 Al of the blood was
collected from the preheated tail-vein of a mouse with a
glass capillary. Eight hours after the test drug formulation
application, mice (n = 4) were killed by heart puncture.
Their dorsal skin was then excised and treated as is
described in Ref. [18].
2.7. Pharmacodynamics
Pharmacodynamics of corticosteroids in mice is conve-
niently assessed by measuring suppression of the chemically
induced ear oedema by a given, topically administered, test
substance [21]. For this purpose, we first injected (10 Al/g
body weight) a mixture containing 6-ml 0.9% NaCl, 1-ml
Ketavet 100 (Parke-Davis, Berlin, Germany) and 0.25-ml
Rompun (Bayer, Leverkusen, Germany) into animals peri-
toneum. We then smeared the given drug amount in a test
formulation over the inner side of one ear of each fully
anaesthetised test animal, leaving thereafter the site to dry.
(When so stated, the ear was wiped free of the formulation
on the skin surface with a cotton swab after 8 h.) At the
specified time after the test drug administration, we applied
the oedema inducing arachidonic acid (5 Al in 5-Al ethanol)
to each ears. The ear that did not receive the test drug served
Table 1
Capability (relative to that of water) of the corticosteroid-loaded very
deformable vesicles, TransfersomesR, liposomes and micelles to penetrate
through the pores approximately three times smaller than the penetrant size
under influence of two different hydrostatic pressuresa
Formulation Low
pressure
(0.2 MPa)
High
pressure
(0.9 MPa)
Micelles 1.1F 0.1 1.1F 0.1
Liposomes 0.0001 0.001
Transfersomes 0.001 1F 0.1
Liposomes with hydrocortisone 0.0001 0.001
TransfersomesR with
hydrocortisone
0.001 1F 0.1
TransfersomesR with
dexamethasone
0.001 1F 0.1
a The artificial barrier consisted of a polycarbonate membrane
perforated by pores of 100 nm diameter. Liposomes and Transfersomes
were of comparable size. The quoted transport efficacy corresponds to the
ratio of aggregate-to-water transport measured under identical conditions
(by high pressure liquid chromatography and gravimetry, respectively).
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ness after local arachidonic acid administration in triplicate,
on living non-anaesthesised animals, with a hand-calliper.
The difference typically amounted to a factor of approxi-
mately 2. We assessed each challenge time-point indepen-
dently. The test animals were sometimes reused, however,
after a washout period of 2–3 weeks, with essentially the
same result.
2.8. Statistics
Most of the reported data are the means of three
independently measured values. The bars in illustrations
represent the standard error of the mean. (When no range is
given, only a single experiment was done.) Statistical
significance was determined using Student’s (paired) t test.
It was deemed to be given when P>0.05. Data analysis was
performed with the software package ORIGIN (Microcal,
OR, USA).3. Results
After initial pre-biological drug carrier adaptability tests,
we compared differential ability of various radiolabelled
drug formulations in murine skin penetration tests in vivo.
Alternatively, the excised porcine skin barrier similarly has
been studied ex vivo. Main study emphasis was on the
temporal and dose dependency of in vivo effects, however,
of hydrocortisone and dexamethasone administered on mu-
rine skin in different formulations.
3.1. Barrier penetration ability of corticosteroid loaded
vesicles
When exposed to a low pressure (0.2 MPa) in front of a
nano-porous barrier, lipid vesicles are only little stressed.
We thus observed that all tested vesicle suspensions under
such pressure flow orders of magnitude less rapidly than
water or a suspension of mixed micelles through the semi-
permeable, nano-porous barrier (Table 1). An approximately
fivefold increase of driving pressure ensured the suspension
of mixed-lipid, deformable vesicles to traverse the barrier at
nearly the same rate as pure solvent or micelle suspension.
In contrast, the trans-barrier flux of conventional liposomes
suspension driven by comparable pressure remained rela-
tively low (Table 1).
3.2. Corticosteroid delivery into skin from various for-
mulations
As an example, we tested the skin crossing ability of
dexamethasone applied with mixed-lipid vesicles or a con-
ventional cre`me formulation. Epicutaneous drug application
(0.04 Ag dexamethasone cm 2) for 8 h in the vesicles on
murine skin produced nearly uniform drug distributionacross the stratum corneum. The average value determined
over five strips was approximately 3% (Fig. 1, left panel).
The corresponding value for the cre`me was similar, 2.5%,
but the decay with depth was markedly, although not
statistically significantly, steeper. Between 20% and 40%
of dexamethasone-derived radioactivity was found in the
stripped murine skin 8 h after epidermal administration of
the drug in the mixed-lipid vesicles, depending on experi-
mental conditions. The value measured with dexamethasone
cre`me was at least 50% lower (data not shown).
We obtained a similar overall picture in ex vivo experi-
ments with dexamethasone on porcine skin (Fig. 1, right
panel). Six hours after an epicutaneous drug application in
mixed lipid vesicles, between 11% and 13% of the drug-
derived radioactivity was found in the skin; 13% were found
in the first tape strip and 11% in the fifth strip. In contrast,
the application of dexamethasone in a commercial cre`me
accumulated 23% of the drug in the first tape strip and only
9% in the fifth strip (data not shown). After the treatment
with cre`me, 18% of the radioactivity was found in the
residual stripped, skin and 2% in the underlying fascia.
The treatment with dexamethasone in very deformable
vesicles led to an accumulation of 10% of the applied
radioactivity in the residual skin and 8.5% in the fascia
(data not shown). The skin treatment for 12 h with a
dexamethasone cre`me formulation accumulated from 9%
to 1% of the drug, respectively, in the outermost 10 tape-
stripped layers of the stratum corneum. For the formulations
comprising very deformable vesicles loaded with the drug,
the accumulation was from 7% to 4%, respectively (data not
shown). This is an appreciable increase in drug transport
compared to a commercial cre`me. Similar improvement is
also attested to by the fact that the total drug amount in the
residual skin increases from 15% to 30% when formulations
containing very deformable carriers are used instead of the
commercial cre`me (data not shown).
Fig. 1. Distribution of dexamethasone-derived radioactivity in the skin of mice (left panel) and one pig (right panel) following topical drug application in very
deformable vesicles (TransfersomesR; closed symbols) or in commercial cre`me (open symbols).
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[18] with a focus on the therapeutic index. When a relatively
high area-dose (10 Ag cm 2) is used, less than 10% of the
hydrocortisone-derived radioactivity is still found in the skin
8 h after the application. At the same time point, 50% of the
dexamethasone derived radioactivity is still found in the
skin (Fig. 2), the remainder being recovered in the bodyFig. 2. Dose-per-area effect for hydrocortisone (lower panel) and
dexamethasone (upper panel), applied on the skin in very deformable
carriers, TransfersomesR, on intracutaneous drug concentration at t = 8 h,
measured separately in the outer skin (the stratum corneum, up-arrow) and
the viable skin tissue (down-arrow). The sum of both values is given by
diamonds. (Straight lines merely should guide the eye.)[18]. Reducing the dosage level by 2 orders of magnitude
increases the amount of hydrocortisone retained in the skin,
as judged by radioactivity count, to nearly 100%. The
radioactivity derived for dexamethasone increases to 75%
(Fig. 2). The relative drug concentration in murine skin is
much higher than in the blood (data not shown), despite the
fact that the treated-to-total-skin area in mice is relatively
small.
3.3. Murine ear oedema suppression by topical cortico-
steroids
We tested the rate and efficiency of corticosteroid deliv-
ery into living skin with very deformable carriers for
hydrocortisone and dexamethasone. An appropriate cre`me
or a lotion applied on a comparable skin was used for
comparison.
3.3.1. Hydrocortisone pharmacodynamics
Hydrocortisone applied epicutaneously in a commer-
cially available creme or a lotion did not suppress the
arachidonic acid-induced murine ear oedema immediately.
The lag time for 50% suppression increased with the
topically used drug dose from 2 to 4.5 h in the tested
range between 2.5 and 10 Ag cm 2. In the middle-time
period (for the three tested doses: 4–8; 4–8; 4–16 h) we
observed a quasi-plateau in the measured suppression
effect. The oedema suppression typically fell below 50%
after approximately 7 h, when hydrocortisone was applied
with a cre`me at doses between 2.5 and 5 Ag cm 2. For 10
Ag cm 2 dose, the 50% activity time increased to 16 h.
Fig. 3. (A) Suppression of arachidonic acid-induced ear oedema in mice by
hydrocortisone applied on the skin in very deformable carriers (Trans-
fersomesR; upper panel, closed symbols) or a commercial cre`me and lotion
(lower panel, open symbols) for a period of 24 h. Mean values (up-
triangles: 10 Ag cm 2; diamonds: 10 Ag cm 2; down-triangles: 2.5 Ag
cm 2) and standard error of the mean (bars) are given. (B) Time
dependency of suppression of the arachidonic acid-induced ear oedema in
mice caused by an epicutaneous administration of hydrocortisone in very
deformable carriers (TransfersomesR; upper panel, closed symbols) or a
commercial lotion (lower panel, open symbols) for 2 days. Mean values and
their standard error are given. [Squares: 2.5 Ag cm 2; for other symbols see
legend to (A).] In most cases: n= 3.
Fig. 4. Dose dependency of hydrocortisone-induced murine ear oedema
suppression 6 h (upper panel) and 16 h (lower panel) after drug
administration on the skin in very deformable carriers (TransfersomesR;
closed symbols) or in commercial cre`me (open symbols). Different symbols
correspond to various independent experiments. Lines represent the
corresponding average values; n= 3. Inset: Areas under the oedema
suppression curve, calculated from the data given in Fig. 3A and B.
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observable oedema suppressing effect after 24 and 32 h, or
less, respectively.
Applying hydrocortisone in very deformable vesicles to
murine ears, and then challenging the treated sites with
arachidonic acid at different times, resulted in 50% reduc-tion of oedema within approximately 2 h (2.5 Ag cm 2) to 4
h (10 Ag cm 2) post drug application. The effect lasted for
at least 17 h (Fig. 3A) and more often close to 48 h (Fig.
3B). For the vesicle-based formulations the plateau width (at
approximately 68%) was nearly dose insensitive (4–16, 4–
24, 4–20 h and three times 8–32 h for the first and second
test series, respectively).
The standard deviation of the results obtained by treating
the skin with hydrocortisone in very deformable vesicles was
less than that observed with hydrocortisone cre`mes. Specif-
ically, we calculated the mean of relative error to be 0.378 and
0.161 (median: 0.153 and 0.142) for the drug in vesicles used
at 10 and 5 Ag cm 2 dose, respectively, and to be 0.838
(median: 0.264) for the cre`me at dose of 10 Ag cm 2.
3.3.2. Hydrocortisone dose dependency
The average oedema suppression mediated by hydro-
cortisone from a cre`me was 38%, 44% and 55% at 12 h,
and 19%, 29% and 49% at 24 h after application of 2.5,
5.0 and 10 Ag cm 2 of the drug, respectively. The
corresponding result obtained with similar hydrocortisone
doses in very adaptable carriers after 24 h was 49%,
68.5% and 66%, respectively. Representing the data
differently: with increasing hydrocortisone dose in a
cre`me, the average oedema suppression in the plateau
region changed from 58% to 51% and 65F 19%. For the
5 Ag cm 2 dose in a lotion, the average oedema-
Table 2
AUC (in % h) calculated from the arachidonic acid-induced oedema
suppression by different hydrocortisone and dexamethasone formulations
applied on murine ears
Formulation Dose
(Ag cm 2)
Hydrocortisone
(% h)
Dose
(Ag cm 2)
Dexamethasone
(% h)
Cre`me 2.5 434 0.45 (2363)a
5 634 0.9 (3282)a
10 1128 6 3038 (>3975)a
TransfersomesR 2.5 1375 0.4 (>3767)a
5 1595 0.8 >5070 (>4645)a
10 >1383
The corresponding pharmacodynamic results are given in (Figs. 3, 5 and 6),
respectively.
a Not wiped.
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cle-based formulation, the average suppression with in-
creasing dose was 54F 6%, 71F 7% or 71F16% and
around 55% (range: 54F 10%, 62F 8%, 50F 11%) in
the first and second set of pharmacodynamic experiments,
respectively.
The tested commercial cre`me-like hydrocortisone prepa-
ration was thus confirmed to be biologically reasonably
active. According to the results of our mouse ear oedema
suppression experiments, the 50% bioactivity level is
reached after 6 h for the drug dose around 7 Ag cm 2Fig. 5. Suppression of arachidonic acid-induced ear oedema in mice by dexameth
panel, closed symbols) or in a commercial lotion (lower panel, open symbols) duri
0.9 Ag cm 2; diamonds: around 0.4 Ag cm 2) and standard error of the mean (b(Fig. 4, upper panel). Interestingly, hydrocortisone in ther-
apeutic practice is often used at doses approaching 200 Ag
cm 2, although the anti-oedema effect in our experience
reaches a plateau at approximately 10 Ag cm 2 (Fig. 4,
upper panel). We found that the anti-oedema effect of
hydrocortisone in commercial cre`me even starts to decrease
for doses above 20–30 Ag cm 2, when measured at a
relatively late time point (t = 16 h). In contrast, the formu-
lation of hydrocortisone in very deformable vesicles is 50%
active at a dosage half that observed for the cre`me at t = 6
h and at a fourth of said dosage at t = 16 h (Fig. 4).
We calculated the area under the curve (AUC) for
hydrocortisone in commercial cre`me to be 434% h, 634%
h, and 1128% h for dosages of 2.5, 5, and 10 Ag cm 2,
respectively. The AUC for the formulations containing very
deformable vesicles is higher, 1375% h, 1595% h, and
1383% h, for the dosage levels of 2.5, 5, and 10 Ag
cm 2, respectively. These data are summarised in Table 2.
3.3.3. Dexamethasone pharmacodynamics
Applying dexamethasone in a topical cre`me to a murine
ear reduced the arachidonic acid-induced oedema to 50%
within less than 4 h for a dose around 1 Ag cm 2, which is
quasi-optimum. The effect lasted for approximately 40
h (Fig. 5). Lowering the applied dose to 0.4 Ag cm 2 kept
the lag time for 50% oedema suppression at 4 h but reducedasone used on the skin in very deformable carriers (TransfersomesR; upper
ng a 3-day period. Mean values (n= 3; diamonds: 6 Ag cm 2; squares: 0.8–
ars) are given.
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the applied dosage in a cre`me to 6 Ag cm 2 retarded the
initial anti-oedema action of the drug; 50% inhibition was
now reached not before 14 h (Fig. 5). In this case, however,
the biological protection, as reflected in the at least 50%
suppression of the arachidonic acid-induced oedema, per-
sisted for at least 72 h.
At the first measured time point, which was 4 h after
dexamethasone application in very deformable vesicles to
murine ear, the arachidonic acid-induced oedema was
already reduced by at least 50%. Similar result was
obtained for both tested drug doses (0.8 and 0.4 Ag
cm 2). The effect lasted for at least 45 h at the low dose
(0.4 Ag cm 2) and for at least 52 h, or longer, at the higher
applied dosage (Fig. 5). We did not investigate the temporal
dependence of the effects caused by 6 Ag dexamethasone
cm 2 for the vesicle-based formulations. The reason is that
this high dose already appears to be in the saturation range
(cf. Fig. 7).
Removing the cre`me applied at the drug dose of 6 Ag
cm 2 by mechanical abrasion (wiping the ear with a
cotton-swab) mimics consequences of natural elimination,
such as arises from contacts with the ambient. In practice,
this also resembles the effect of using a lower dosage of
dexamethasone on the skin. The 50% oedema suppression
level for the skin ‘‘cleaned’’ after 8 h is reached after 13Fig. 6. Effect of the residual drug and vehicle elimination from the skin surfac
deformable carriers (TransfersomesR; upper panel: 0.8 Ag cm 2; crossed symbols,
symbols, after wiping). n= 3–4.h and lasts for approximately 18 h. When dexamethasone is
applied on the skin in very deformable vesicles at drug
dose of 0.8 Ag cm 2, and the ear is wiped clean 8 h later,
the 50% level of oedema suppression is achieved after 4 h.
The effect remains at this level or higher for at least 96
h (Fig. 6).
The standard error of the mean for dexamethasone in
very deformable vesicles is significantly lower (mean:
0.197; median: 0.223) than the relative scattering detected
with dexamethasone creme (mean: 0.774; median: 0.753) at
the tested dose.
3.3.4. Dexamethasone dose dependency
The average suppression of oedema by dexamethasone
applied in a cre`me for the 24 h period was 73%. This is
somewhat lower than the average value of 79% for the drug
application with very deformable vesicles, but neither the
measured absolute difference nor the calculated standard
error deviation is statistically significant.
A commercial dexamethasone cre`me achieves 50% oe-
dema suppression 16 h after application of the drug doses
between 0.2 and 0.4 Ag cm 2, depending on the experiment
(Fig. 7, lower panel). If the observation period is shortened
to 6 h, the applied drug amount must be increased to 0.6 Ag
cm 2 barely to reach similar suppression (Fig. 7, upper
panel). Dexamethasone in very deformable vesicles ensurese at different times after a topical treatment with dexamethasone in very
after wiping) or in a commercial cre`me (lower panel: 0.8 Ag cm 2; crossed
Fig. 7. Dose dependency of dexamethasone-induced murine ear oedema
suppression 6 h (upper panel) and 16 h (lower panel) after epicutaneous
drug administration in very deformable vesicles (TransfersomesR; closed
symbols) or in commercial cre`me (open symbols). Different symbols
correspond to independent experiments. n= 3.
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range—between 0.003 and 0.15 Ag cm 2—after 16-h drug
action. Oedema suppression measured after only 6 h reveals
no clear dose dependency (cf. Fig. 7). There are also
difficulties in obtaining reliable values for the higher drug
doses, due to the inverse dose versus speed of action curve
especially for the cre`me (with increasing dosage there is a
slowing of the biological action). No doubt exists, however,
that at all time points for all tested doses the effect of drug
applied on the skin with very deformable vesicles greatly
exceeds the effect of the drug from a commercial cre`me.
Experiments performed at 1 h after drug administration
had similar dose dependency for the formulations with very
deformable vesicles, reaching a maximum activity of 20%,
and a less pronounced, but comparable effect to that
observed with the cre`me in the 8-h trials (data not shown).
The AUC for dexamethasone in the tested commercial
cre`me is calculated to be 2363% h, 3282% h, and >3975
(range: 2905;5044)% h for dosages of 0.45, 0.9, and 6 Ag
cm 2, respectively. These values were calculated for max-
imum times reaching 52, 62 and 72 h, respectively. Wiping
the ear after 8 h reduces the 6 Ag cm 2 AUC value
pertaining to the 72-h observation to 3038 (range:
1035;4005)% h. The AUCs measured for the formulations
containing very deformable vesicles have values of 3767%
h and 4645 (3810;5480)% h at 72 h for the much lower
dosages of 0.4 and 0.8 Ag cm 2, respectively. If the
ear is wiped 8 h after very deformable vesicles with
the drug (0.8 Ag cm 2) application, the AUC is 5070(range: 4194;5947)% h at 72 h (cf. Table 2). This shows a
lower sensitivity of the vesicle-based formulation to me-
chanical abrasion in comparison to commercial cre`me.4. Discussion
Several research groups have published papers on topical
corticosteroid delivery by means of liposomes [7–12]. In
spite of initial enthusiasm on liposomal corticosteroid der-
matics [22], no corresponding drug has been commercial-
ised to date. One possible reason for this is the lack of
consistency in the alleged therapeutic advantages of liposo-
mal corticosteroid dermatics. It is unclear whether or not the
improvement in the therapeutic index of liposome-based
drugs observed in some studies is due to an improved drug
retention in the skin or else is a consequence of the less
direct effects of liposome components on the organ [23].
Phosphatidylcholine, for example, has been reported to
improve indirectly the bioavailability of epicutaneously
applied corticosteroids [23]. It is even possible that some
of positive observations are experimental artefacts [15]
caused by the neglect of lipid deposit on the skin surface.
No doubt exists, however, that at least some corticoste-
roids reach greater depth in the skin when the drug is applied
with certain [7–9], e.g. skin-derived [10], liposomes. Spe-
cifically, Fresta reported an f 11 times and f 19 times
higher drug concentration in the dermis when dipalmitoyl-
phosphatidylcholine and skin-lipid liposomes were used for
0.75–3 h, respectively [10]. This observation has an unclear
meaning, however, as the applied drug dose in Fresta-study
was 1–2 orders of magnitude above the commonly used dose
(75 Ag cm 2 when measuring biodistribution in pre-frozen
skin samples and 500 Ag cm 2 in skin blanching studies in
vivo). Lack of difference between fluid phase skin-lipid and
gel-phase phosphatidylcholine vesicles, which are known to
have very different skin penetration ability [29], is also
perplexing. It is therefore probable that Fresta did not
measure direct drug diffusion but rather observed drug
transport modulated by liposomes and possibly and enhance-
ment by an unidentified lipid-derived skin permeation en-
hancer. This may explain the discrepancy between Fresta’s
and other groups findings [11,12,24]. For example, Kim et al.
[11] reported that hydrocortisone absorption in the skin from
a liposome gel is lowered compared with the conventional
ointment formulation. The same researchers also reported an
absorption peak at 45 min with a trend towards prolongation
of drug permeation.
The biodistribution and the pharmacokinetics of directly
or intravenously administered hydrocortisone, dexametha-
sone, and triamcinolone-acetonide in very deformable
vesicles were compared in our previous study [18]. Both
kinds of drug application gave a similar biodistribution of
the drug-derived radioactivity.
In this contribution, we provide complementary informa-
tion, suggesting that corticosteroids enter the skin best when
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this the case?
The data given in Table 1 suggest that sufficiently high
driving pressure prompts complex, very deformable
vesicles, but not simple liposomes, to start flowing through
a barrier with pores significantly smaller than the average
vesicle diameter. The passage is arguably enabled by the
stress-dependent vesicle deformation in front of or in the
core of a pore. No comparable flux is seen for the simple
liposome suspensions. The difference is indicative of a
unique, self-regulating mixed-lipid vesicle response to non-
uniform stress near or in a narrow pore [13,15].
When a complex, very deformable vesicle is forced into a
biological orifice, such as an inter-corneocyte constriction in
the stratum corneum, the aggregate components redistribute
nonuniformly, making the carrier locally more deformable.
The vesicle thus adjusts itself to the inhomogeneous sur-
rounding stress: the components that tolerate such a stress
better are concentrated while the less tolerant substances are
depleted from the most deformed sites. A very deformable
vesicle can therefore adapt its form to inter-corneocyte
pathway shape and therefore pass through the orifice rela-
tively easily [27,28]. The very deformable agent carriers
consequently cross the skin barrier through the hydrophilic
intercellular pathways [26] that are too narrow to be
penetrated by the less adaptable lipid aggregates, such as
liposomes. Data given in Table 1 together with pharmaco-
dynamic results corroborate there conclusions.
The water activity gradient in the skin points from the
surface into the skin and falls rather rapidly through the
outermost layers of the organ [27]. The rate and the efficacy
of the resulting hydrotactic motion of very deformable
vesicles are therefore independent of the applied drug
concentration. This permits the selected corticosteroid con-
centration to be lowered to the level fixed by the intrinsic
drug activity and not by the need to maximise the trans-
epidermal drug transport by keeping the superficial drug
concentration high. Corticosteroid formulations with an
unusually low agent content are therefore feasible and useful
the very deformable TransfersomeR carriers. Resulting
therapeutic products are thus expected to have excellent
bio-tolerance, also due to the fact that they contain no skin
permeation enhancers.
Once they have reached the wet, viable epidermis, the
very deformable vescicles loaded with corticosteroids expe-
rience no further inward water activity gradient [15,16].
Consequently, any spontaneous carrier motion ceases in this
skin region. The viable skin hence acts as a local reservoir
for the carrier-mediated drug. The reservoir is partially
identical to the site of desired biological action, and not
subject to the further limitations on the diffusion through the
stratum corneum. Our data, reported in Fig. 2, support the
hypothesis.
The intracutaneous fate and the activity of the carrier-
transported corticosteroids depend upon agent solubility in
this compartment. Drugs such as hydrocortisone (low lip-ophilicity) have a tendency to leave the carrier and the
diffuse into the surrounding hydrophilic environment.
Therefore, these agents do not have a long biological half-
life in comparison to the more lipophilic drugs. A reference
to the difference in biological half-lives observed with
hydrocortisone (the half-life for elimination is 1.5 h) or
with the longer circulating dexamethasone (elimination half-
life in mice between 1.5 and 3 h). These data must be
analysed with care, however, as they are based upon
radiolabel distribution data.
Hydrocortisone is a steroid hormone secreted by the
adrenal cortex and was approved as a drug by FDA in
1951. The commercial drug forms include the unchanged
hormone and different salts thereof (acetate, cypionate,
sodium phosphate, butyrate, valerate, and sodium succi-
nate), which are being used in a variety of galenic formu-
lations. Wohlrab and Lasch described an improvement of
hydrocortisone penetration into the skin after drug applica-
tion in liposomes in a series of publications [7–9]. The
small sample size in our biodistribution studies and other
experimental differences preclude quantitative comparison
of our and Lasch’s findings, but use of vesicles on the skin
seems to produce generally more favourable corticosteroid
distribution in outer skin layers.
Locally absorbed hydrocortisone starts to be metabolised
in the skin. Systemic hydrocortisone is quickly distributed
into the kidneys, intestines, muscle, and liver, and is mainly
metabolised in the latter organ, to inactive metabolites [1].
All inactive hydrocortisone metabolites, as well as a small
portion of unchanged drug, are excreted in urine. The
circulating drug is mainly bound to plasma proteins, only
the unbound portion of a dose being active.
Dexamethasone (approved by FDA in 1958) and its
derivatives are synthetic glucocorticoids used as anti-inflam-
matory or immunosuppressive agents. Dexamethasone is
available as oral, parenteral, topical (spray), and ophthalmic
dosage forms. Dexamethasone from topical preparations
metabolised in situ (the skin, the eye) whereas the systemic
drug is metabolised in the liver to inactive metabolites.
These inactive metabolites, as well as a small portion of
unchanged drug, are excreted in urine.
The degree of drug retention in the skin is likely to be
much higher in humans, with more favourable treated-skin
to total body-weight ratio, than on mice. The therapeutic
dose per area of the synthetic corticosteroid dexamethasone
in very deformable vesicle formulations is at least 10 times
lower than that required for the use with commercial
preparation. This allows us to postulate that most of the
drug will be confined to human skin and that the danger of
systemic side effects will be reduced.
Both hydrocortisone and dexamethasone administered in
very deformable vesicles suppress ear oedema more rapidly
than the corresponding topical cre`mes or lotions. Moreover,
the drug’s biological effect persists longer if very deformable
carriers are used. Another advantage is the reduced dosage of
the corticosteroid necessary to reach certain therapeutic
G. Cevc, G. Blume / Biochimica et Biophysica Acta 1663 (2004) 61–73 71effect, i.e. the increased relative drug potency effect. We have
calculated that the maximally used daily dose could be
reduced to 1 mg for dexamethasone and to below 20 mg
for hydrocortisone. The latter upper limit is comparable to the
natural production of hydrocortisone in humans (12 to 30mg/
day [1]). Such dosage therefore should be well tolerated in
adults and infants, especially as the majority of the drug
remains in the skin (cf. Fig. 2).
Equivalent dose for dexamethasone and hydrocortisone
used in conventional formulations is 0.5 and 25 mg [2],
respectively, yielding relative potency factor of 50 based on
the results of vasoconstriction studies. We determined the
equivalent dose ratio for these drugs in very deformable
carriers, using murine ear oedema suppression test, to be
around 60 (cf. Figs. 4 and 7), which gives credence to our
assay.
The relative drug potency and local drug action thus
changes in the opposite direction as the half-life of both
tested drugs (cf. Fig. 8). So does the typically used drug
concentration in conventional products. (The commercial
dose range is 0.03–0.1% for dexamethasone- and 0.25–
2.5% (mainly 1%) for hydrocortisone-containing commercial
preparations.) All these values are far above the concentra-
tions useful in the corresponding vesicle-based formulations,
which are estimated to be below 0.01 wt.% and around 0.1
wt.%, respectively.
The dose per area could be reduced from conventional
dosages by up to a factor of 10 by utilising formulations
containing corticosteroids in very deformable carriers.
This should reduce the intracutaneous corticosteroid con-
centration to the range of 1 Ag/g (for high potency drugs)
to 10 Ag/g (for low potency drugs). As a result, drug
concentrations very close to the 0.25 Ag/g concentrationFig. 8. Comparison of drug pharmacokinetics (right panel) with the time depende
(upper half) and dexamethasone (lower half), all measured in mice (n= 4–5).of corticosteroids in normal human blood would be
reached.
It stands to reason that drug delivery mediated by very
deformable carrier shall reduce the side effects that are often
observed with conventional corticosteroid therapy. For ex-
ample, the naturally occurring corticosteroid, hydrocorti-
sone, does not cause a significant skin atrophy even after
long time use; when used on a large area, however, it can
lead to various undesired systemic side effects, however.
Unfortunately, the currently available hydrocortisone in
cre`me/ointment/lotion formulations has too low potency for
an effective therapy of most common, but severe, dermato-
logical diseases. Raising the concentration of epicutane-
ously applied hydrocortisone has no beneficial effects,
probably due to saturation of the bioactivity of the drug at
dosages exceeding 10 Ag cm 2 (see Fig. 4). In this context,
it is worth noting that absolute potency of hydrocortisone in
very deformable carriers appears to exceed that of the drug
in commercial cre`mes or lotions. By comparing the average
pharmacodynamic effects in ‘‘plateau region’’ (cf. Fig. 3A
and B), we conclude that the increase over cre`me- and
lotion-like formulations amounts to approximately 13% and
28%, respectively. From the direct dose–effect study done
after 6 (16) h (cf. Fig. 4), the increase is estimated to be 22%
(50%). If one uses the 24-h average for comparison, the
increase is 60% (cf. Fig. 3A and B).
The standard deviations in experiments with very de-
formable drug carriers are smaller than the variability in
tests with conventional formulations. This suggests that
corticosteroids delivered with the more novel carriers have
more reliable action, probably due to improved target
specificity of such vesicle-based formulations. One can even
speculate that the use of very low dosages of corticosteroidsnce of drug-induced ear oedema suppression (left panel) for hydrocortisone
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of the drug into hyperactive cells in the skin, which take up
particulate material most avidly. This would divert drug’s
action from the normal to the inflammatory cells, and thus
could improve the therapeutic index of the corticosteroids
delivered in such a way.
Rapid drug transfer into the skin and slow subsequence
drug transfer into the blood capillaries, which are indirectly
documented in Fig. 8, explain the faster onset of the desired
oedema-suppression the retarded begin of the less desirable
vasoconstriction, observed with the formulations containing
very deformable vesicles is another consequence of this.
Indeed, vasoconstriction is the first sign of drug spillover
into blood circulation.
It is therefore important, and reassuring, that our value
for the equivalent dose ratio for hydrocortisone and dexa-
methasone is realistic. We determined this ratio in murine-
ear oedema-suppression tests to be around 60. Such value is
rather close to the published ratio of 0.5/25 = 50 stemming
from vasoconstriction measurements in humans [2]. Murine
ear oedema suppression data thus appear to be relevant for
planning human clinical trials.5. Conclusions
In this publication we have supplied conclusive evidence
for the efficacy and therapeutic value of corticosteroids
hydrocortisone and dexamethasone formulations based on
very deformable carriers. The resulting advantages are mul-
tiple and include a faster onset of anti-oedema effects; longer
action times; bioactivity that is unaffected by the mechanical
drug abrasion; and, most importantly, the ability to drastically
(at least by a factor of 10) reduce the necessary dosage that
ensures therapeutic, and perhaps better, effects. Use of the
described ultra-adaptable carriers, TransfersomesR, therefore
might reduce the amount of systemic side effects and allow
use of dexamethasone in situations where such drug previ-
ously was not considered due to the risks of its side effects.
Similar carriers will potentially also allow use of the naturally
occuring and well tolerated hydrocortisone in situations
where it was not previously employed due to its relatively
low biological potency. Last but not least, application of very
deformable vesicles introduces a new method of use for
therapeutically treating skin diseases, while offering unprec-
edented opportunities for modern, well-controlled, topical
skin medication with the reduced frequency of application.Acknowledgements
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